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Abstract
Mother-to-child transmission of cytomegalovirus (CMV) and varicella zoster virus (VZV) can 
lead to severe birth defects and neurologic impairment of infants. Congenital CMV is the most 
common congenital infection and the leading infectious cause of infant hearing loss and 
neurologic deficits, complicating up to 1% of all pregnancies globally. While antiviral treatment of 
congenitally CMV-infected infants can ameliorate the CMV-associated hearing loss and 
developmental delay, interventions to prevent congenital CMV infection and the associated 
neurologic impairments are still being evaluated. Moreover, an effective CMV vaccine to protect 
mothers against CMV acquisition during pregnancy is urgently needed to reduce the sizeable 
health and economic burden of this disease. In contrast, congenital VZV infection is rare, 
attributable to the availability of an effective VZV vaccine, high rates of preexisting VZV 
immunity prior to pregnancy, and poorly efficient in utero VZV transmission. Moreover, passive 
immunization of exposed pregnant women or infants with VZV hyperimmune globulin can 
prevent severe disease in those that do not have prior immunity. Active and passive immunization 
strategies to prevent perinatal CMV infection with similar efficacy to those established to prevent 
perinatal VZV infections are a critical need in pediatric health.
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Human CMV is a highly ubiquitous pathogen, with a 45–100% adult seroprevalence rate 
worldwide [1]. Additionally, CMV is the most common cause of congenital infection, 
affecting 0.5–2% of all live-born infants [2]. While the majority of affected infants are 
asymptomatic at birth, 10–15% exhibit signs of CMV-associated sequelae including 
thrombocytopenia, hepatitis, chorioretinitis, sensorineural hearing loss (SNHL), intrauterine 
growth restriction, and mental retardation (Figure 1) [3, 4]. An additional 5 to 15% of 
asymptomatic CMV-infected infants will develop late-onset sequelae, most commonly 
SNHL, within the first two years of life [3]. Altogether, congenital CMV accounts for 25% 
of all cases of childhood deafness and results in more long-term pediatric disabilities in U.S. 
children than any other common causes of birth defects, including Down syndrome and 
spina bifida (Fig. 2) [4]. Several maternal factors (Table 1) are known to increase the 
incidence and severity of congenital CMV disease, of which maternal CMV immune status 
plays an important role. In cases of primary maternal infection, where there is no pre-
existing immunity, 40% of women transmit CMV in utero compared to only 1–2% of CMV-
seropositive women [5]. Furthermore, neurologic deficits are more common following 
primary maternal CMV infection, and results in the most severe fetal disease outcomes [5].
Also at risk for developing severe CMV-associated sequelae are premature infants that 
acquire CMV postnatally either through exposure via breast milk or blood transfusions. 
While breast milk transmission of CMV is asymptomatic in full-term infants, postnatal 
acquisition in very low-birth-weight premature infants can be associated with a sepsis-like 
illness with sequelae including pneumonitis, enteritis, thrombocytopenia, and hepatitis [6, 
7]. Although transfusion-associated postnatal CMV infection of premature infants has nearly 
been eliminated by the use of leukoreduced and CMV-seronegative blood products, 
encouragement of breast milk feeding to improve health outcomes for premature infants has 
potentiated the need to address breast milk transmission of CMV in neonatal intensive care 
settings [8]. However, it remains unclear if postnatal CMV infection of premature infants 
results in long-term deficits.
Varicella zoster virus (VZV), like CMV a member of the herpesvirus family, can lead to 
adverse pregnancy and infant outcomes when transmitted following acute maternal infection 
during pregnancy. Though preexisting VZV immunity has remained high in pregnant 
women both before and after the advent of VZV vaccination, immunity to VZV is 
standardly documented during early pregnancy. Infants with the highest risk of acquiring 
VZV are born to women with acute infection appearing between five days before and two 
days following delivery, as the infant is exposed to VZV at birth in the setting of limited or 
no placental VZV-specific IgG transfer. Rarely, VZV can be transmitted in utero during a 
primary maternal infection, and if this occurs in the first 20 weeks of pregnancy, fetal 
demise, intrauterine growth restriction, hydrops, limb deformities, microcephaly, and other 
neurologic defects can result from the congenital infection (Congenital Varicella Syndrome) 
[9].
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An estimated 0.7% of all live-born infants are born with congenital CMV infection. Ten to 
15% of congenitally infected infants will display symptoms at birth [10] and half of these 
symptomatic CMV-infected infants will suffer long-term sequelae, often SNHL, mental 
retardation and microcephaly [2]. Furthermore, 10% of infants who are asymptomatic at 
birth develop CMV-associated SNHL early in life and approximately 5% are reported to 
have additional cognitive defects, making it a leading cause of pediatric long-term disability 
in U.S children (Figure 2) [10].
The incidence of birth defects and pediatric neurologic abnormalities attributable to 
congenital VZV infection is considerably lower than that of CMV, as the U.S. maternal 
CMV seroprevalence is approximately 50% compared to greater than 90% for VZV, leaving 
more women at risk of acute CMV infection during pregnancy. Moreover, the rate of 
congenital transmission of CMV following acute primary maternal infection is 
approximately 40%, compared to less than 2% following acute maternal infection with VZV 
[9, 11].
World Wide/Regional Incidence and Mortality Rates
The incidence of congenital CMV transmission is greatly impacted by CMV seroprevalence 
in women of childbearing age. In populations of low socioeconomic status (SES), CMV 
prevalence in pregnant women can reach as high as 80–100% [1]. As approximately two 
thirds of congenital CMV transmissions occur in CMV-seropositive women, the incidence 
of congenital CMV infection is high in populations of low socioeconomic status and high 
CMV-seroprevalence, averaging 1.2% in comparison to the worldwide incidence rate of 
0.7% [10]. In the U.S., where CMV seroprevalence is close to 50% in women of 
childbearing age, there is an increase in the number of primary maternal CMV infections 
during pregnancy, and as a result more severe infant outcomes [12]. Mortality in infants due 
to congenital CMV infection ranges from 100–200 in the U.S. each year [13].
Clinical Correlation
Maternal interventions for the prevention/treatment of congenital CMV and perinatal VZV 
infections
Routine prenatal CMV screening is not currently recommended given the lack of a proven 
effective intervention to prevent congenital CMV [14, 15]. Furthermore, differentiating 
primary infection from re-infection or reactivation is difficult due to the poor reliability of 
IgM antibody assays. With a sensitivity ranging from 50–90% and a high rate of false 
positivity, IgM is detectable in < 30% of women with an actual primary infection [16–18]. 
Additionally, IgM can be detectable during reactivation or re-infection and can persist for 
many months following a primary infection [18, 19]. Maternal immunity demonstrated by 
IgG positivity alone does not eliminate the potential for congenital CMV since two-thirds of 
cases result from re-infection with a new CMV strain or reactivation of latent virus [20]. The 
addition of IgG avidity, a measure of antibody maturity, significantly improves the ability to 
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identify primary infection [21]. The detection of IgM and IgG combined with low IgG 
avidity suggests a primary CMV infection occurring in the past 2 – 4 months [16, 22].
In addition to vaccine development (see section below), there is ongoing research to 
determine the potential effectiveness of CMV-specific hyperimmune globulin (HIG) in 
congenital CMV treatment (Table 2). Initially, Nigro et al. demonstrated some promise for 
the possible efficacy of CMV-HIG in treating congenital infection, though this was a cohort 
study [23]. Revello and colleagues recently completed a trial of 124 pregnant women with 
documented primary CMV infection randomized to receive serial CMV-HIG infusions or 
placebo. Thirty percent of the CMV-HIG group delivered infants with congenital CMV 
compared to 44% in the placebo group, which while encouraging, was not statistically 
significant likely due to inadequate power [24]. Two large-scale ongoing randomized trials 
of CMV-HIG to prevent congenital CMV will hopefully provide definitive evidence as to its 
potential efficacy [25, 26].
In lieu of vaccination or effective antenatal treatment, prevention or reduction in congenital 
CMV must focus on educating all women of childbearing potential on preventive strategies. 
There are several risk factors for infection including lower SES, history of sexually 
transmitted infections including HPV/abnormal cervical cytology, and very young maternal 
age (< 15 years). Women at higher risk for primary infection include child care workers and 
those with young children in the home. In one study, eleven percent of seronegative child 
care workers seroconverted within the first year of employment [27]. Yeager et al. showed 
that over half of all family members of young children seroconvert within a year [28], and 
increasing parity was shown to be an independent risk factor for CMV seroconversion [29]. 
All women of childbearing potential, regardless of the presence or absence of risk factors, 
should be counseled that their personal risk of CMV acquisition can be significantly reduced 
with proper hygiene and behavioral practices.
Regarding VZV, prior history of infection is 97–99% predictive of seropositivity, which 
confers long-term immunity [30]. Thus, routine prenatal VZV screening based on reported 
history combined with serology during early pregnancy is recommended [30]. Women who 
are VZV-seronegative should be vaccinated postpartum. Such a strategy is supported by 
cost-effectiveness and cost-benefit analyses, given that the associated morbidity and 
mortality are very high and there is potential for prophylaxis/treatment to prevent congenital 
infection [31, 32]. If non-immune, a pregnant woman should be advised to avoid contact 
with infected individuals until they are non-infectious [30]. If a susceptible pregnant woman 
has exposure to a chickenpox-infected individual, varicella immunoglobulin (VZIG) should 
be administered within 96 hours of exposure to prevent infection and reduce infant 
morbidity and mortality [33]. Although unproven through randomized clinical trials, 
prevention of maternal VZV infection theoretically should prevent congenital VZV. Non-
pregnant women of childbearing potential should have documentation of prior history of 
chickenpox in their medical record with preconception vaccination if no such history exists 
or if documented IgG negative.
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Infant interventions for the prevention/treatment of congenital CMV and perinatal VZV 
infections
Maternal VZV-specific IgG is highly effective in protecting the infant against neonatal and 
congenital VZV infection. There are a few settings in which post-exposure prophylaxis with 
VZIG is recommended for infants who are deficient in maternal VZV-specific IgG. One 
such scenario is primary maternal infection near the time of delivery, which can lead to 
severe disease in the newborn, and up to 30% mortality [34]. Similarly, VZIG should be 
administered to infants born to non-immune mothers and all premature infants born < 28 
weeks of gestational age who are postnatally exposed to an individual with acute VZV 
infection, as both of these settings leaves the infant without maternal antibody protection. If 
infection occurs in an infant that is deficient in VZV-specific maternal IgG, antiviral 
treatment with high dose acyclovir should be initiated [35].
There are no currently well-established methods to prevent congenital CMV transmission 
(see maternal interventions). Yet, as CMV-associated neurologic complications continue to 
develop throughout the first two years of life in congenitally-infected infants, antiviral 
suppression of CMV replication may prevent or ameliorate some of these sequelae. The 
Collaborative Antiviral Study Group (CASG) performed a clinical trial in congenitally 
CMV-infected infants with CMV-associated disease in the central nervous system with six 
weeks of intravenous ganciclovir, an antiviral that specifically targets the CMV 
phosphotransferase UL97, compared to no treatment [36]. This study demonstrated clear 
improvement in hearing outcome for the ganciclovir-treated infants, though neutropenia, a 
known side effect of this drug, occurred in two-thirds of the infants treated with ganciclovir. 
While the clinical improvements with ganciclovir treatment were promising, this long-term 
intravenous treatment was challenging to implement in infected infants who typically do not 
require long-term hospitalization. Thus, the same group performed a pharmacokinetic study 
comparing intravenous ganciclovir with the oral ganciclovir prodrug valganciclovir in 
neonates. Oral valganciclovir administration was found to achieve similar plasma levels of 
the active drug and had a similar side effect profile to that of intravenous ganciclovir, thus 
providing a practical oral option for treatment of congenital CMV disease [37]. In a 
comparison of infant hearing and developmental outcomes after six weeks versus six months 
of oral valganciclovir treatment, [38]. oral valganciclovir treatment until six months of age 
led to improved hearing and developmental outcomes for CMV-infected children. 
Moreover, the incidence of neutropenia was similar in the placebo and valganciclovir-
treated groups between 6 weeks and 6 months of treatment, suggesting that the neutropenia 
in valganciclovir-treated infants may be at least partly attributable to the viral infection 
itself. Thus, congenitally CMV-infected infants exhibiting CMV-associated neurologic 
sequelae should receive valganciclovir treatment and followed closely for suppression of 
viremia and hematologic abnormalities. However, as 10–15% of congenitally-infected 
infants who are asymptomatic at birth will develop CMV-associated neurologic sequeale 
(namely hearing loss) before two years of age, more work is needed to determine whether 
asymptomatic infants will benefit from this antiviral treatment. Furthermore, it is not known 
whether premature infants who experience symptomatic postnatal CMV infection via breast 
milk feeding benefit from antiviral treatment.
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The advent of a safe, oral option for effective CMV antiviral treatment for congenitally-
infected infants, combined with the high burden of congenital CMV as a major contributor 
to pediatric disabilities, has made it more critical to institute standard, routine CMV testing 
so that all congenitally-infected infants may be evaluated for potential antiviral treatment 
that could impact their future cognitive abilities. As infant serologic assessments are plagued 
with issues including the presence of maternal IgG and the poor performance and predictive 
capacity of CMV-specific IgM, detection of the virus is a more practical approach. The 
current standard of diagnosing congenital CMV infection in infants is a CMV culture from 
the urine or saliva, including rapid virus detection in culture via immunohistochemistry. Yet, 
this diagnostic technique is labor-intensive and challenging in laboratories with limited 
tissue culture facilities. Boppana and colleagues have made considerable progress in 
developing a high throughput saliva or urine quantitative real time polymerase chain 
reaction (PCR) assay is highly-sensitive and specific for CMV detection compared to the 
gold standard of urine CMV culture [39, 40]. While implementation of CMV PCR of dried 
blood spots would have been a convenient way to integrate this testing into the standard 
newborn screening program, this assay was found to have low sensitivity [41]. The saliva 
real time PCR, however, has been validated on dried saliva spots, facilitating batched 
sample analysis [39]. Therefore, as large scale infant CMV testing is feasible, and treatment 
of congenitally-infected infants is proven to benefit their long term outcome, the 
implementation of universal screening for congenital CMV infection is now a top priority 
for improving pediatric health.
Prospects and Priorities for Maternal CMV Vaccine Research
The large number of infants severely affected by congenital CMV transmission, and the 
substantial economic burden associated with long-term treatment and care of children with 
CMV-associated disabilities has prompted the Institute of Medicine to recognize the 
development of a maternal vaccine to be of the highest priority [42]. However, despite 
continuous vaccination efforts for the prevention of CMV infection for nearly 40 years, 
clinical trials still remain at the earliest stages. Summarized below and in table 3 are the 
important successes and failures of previous vaccination attempts that inform the new 
directions for current and future CMV vaccine research.
Live-attenuated CMV vaccines
Vaccination against CMV infection began in the early 1970’s with two live-attenuated 
vaccine candidates, AD169 and the well characterized Towne strain, both of which 
underwent extensive passaging in human fibroblasts before being tested in humans [43, 44]. 
Symptoms following vaccination with either strain were mild and restricted to the site of 
injection and did not result in virus shedding or latency in any of the groups tested, therefore 
proving to be safe and well tolerated [42–48]. Furthermore, it was discovered that among the 
different routes evaluated, subcutaneous vaccination was the most effective at inducing the 
production of CMV-specific neutralizing antibodies and lymphoproliferative cellular 
responses [43, 44, 49, 50]. Vaccine efficacy of the live-attenuated Towne strain was 
analyzed in two high risk populations including seronegative renal transplant candidates 
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receiving seropositive donor organs, and seronegative women of childbearing age with 
young children attending day care. Multiple independent studies in renal transplant 
recipients reported that vaccination with the Towne strain prior to transplantation did not 
alter the rate of CMV infection in comparison to non-vaccinated individuals, however 
vaccination did reduce the severity of disease following primary CMV infection by 84–
100% according to a pre-established scoring system [51]. Similarly, vaccination with the 
Towne strain in seronegative women with children attending day care also failed to protect 
the women from acquiring CMV, yet child-to-mother transmission was rarely detected in 
naturally seropositive women [46]. This last observation suggested the Towne vaccine was 
incapable of eliciting wild-type like immunity, a common problem in the majority of live-
attenuated clinical vaccine trials. To address this issue, recent efforts have been made to 
elicit a stronger and longer-lasting immune response to CMV with the Towne vaccine that 
include the addition of an IL-12 adjuvant and the creation of several Towne chimeric viruses 
encoding portions of the genome found in other non-attenuated strains, neither of which 
have been successful at achieving wild-type immunity [53, 54].
CMV subunit vaccines
The majority of subunit vaccines to date have focused primarily on the surface glycoprotein, 
gB. The gB protein is directly involved in the attachment and entry of CMV into fibroblasts, 
and is a major target of neutralizing antibodies present in seropositive plasma. In the first 
human gB vaccine trial, soluble gB was administered to seronegative adults with either a 
squalene and water emulsion adjuvant MF59, or aluminum hydroxide [52]. The recipients 
were given varying doses of the vaccine in three different regimens. Mild discomfort at the 
site of injection was common, but no serious side effects were reported in any of the 
treatment groups. Scheduled immunizations at 0, 1, and 6 months elicited the highest 
neutralizing antibody response between 2 and 6 months after the final dose, and was 
strongest when combined with MF59. Moreover, the level of neutralizing antibodies induced 
after the third dose of the gB/MF59 vaccine was above that of naturally infected, 
seropositive individuals. In a Consistent with this finding, children receiving the same gB/
MF59 vaccine regimen at 0, 1 and 6 months were also shown to produce neutralizing 
antibody titers that exceed those seen in naturally immune sera [53]. In a cohort of CMV-
seropositive women, the gB/MF59 vaccine was also capable of boosting antibody and CD4-
T cell immune responses [54]. Data from these studies, and its proven safety in transplant 
recipients, prompted the first and only phase 2, placebo-controlled, randomized, double-
blinded trial in seronegative women [55]. Over 400 women were vaccinated with the gB/
MF59 vaccine or placebo within 1 year of giving birth, and thus were at high risk for 
acquiring primary infection. After 42 months, 18/225 vaccinated women and 31/234 
placebo-treated women had experienced a CMV infection, yielding a vaccine efficacy of 
50%. Among the women in this study, 81 vaccinees and 97 placebo recipients became 
pregnant. Only 1 of 81 infants born to vaccinated women had confirmed CMV infection and 
was non-symptomatic. Three infants were born with CMV infection in the placebo-treated 
group, one of which presented severe sequelae at birth, while the other two remained 
asymptomatic. Although the numbers in this study are too small to evaluate the efficacy of 
the gB/MF59 vaccine on preventing mother-to-child transmission of CMV in seronegative 
women, the results are promising and encourage a future phase 3 trial.
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With the present knowledge that CMV contains multiple glycoprotein complexes on the 
surface of virions involved in cell entry, it is unlikely that production of neutralizing 
antibodies to a single glycoprotein will provide broad protection against all CMV isolates. 
Therefore, recent emphasis has been placed on the development of a vaccine that elicits 
neutralizing antibodies to a second glycoprotein complex consisting of gH, gL, UL128, 
UL130 and UL131 important for epithelial cell tropism [56]. These studies are still in early 
preclinical evaluation. Future vaccine platforms that include both the gB protein and 
pentameric complex as targets will be key to determining the immune responses required for 
protection against maternal infection and congenital transmission of a breadth of CMV 
variants. Additional vaccine strategies currently underway include CMV vector and DNA 
vaccines aimed at eliciting both neutralizing antibody and cell-mediated immune responses 
[57–60].
Summary/Discussion
While effective interventions to prevent perinatal VZV infection exist, strategies to prevent 
congenital CMV infection are urgently needed to reduce the high pediatric health and 
economic burden of this common congenital infection. Long-term antiviral treatment can 
improve hearing and developmental outcomes for congenitally CMV-infected infants, yet do 
not prevent the life-long neurologic impairment. The development of active and passive 
vaccine strategies for impeding maternal CMV acquisition and placental transmission is key 
to eliminating this common and potentially-preventable cause of pediatric disabilities.
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• Congenital CMV infection is the leading infectious cause of hearing loss and 
neurologic deficits, affecting up to 1% of all pregnancies worldwide.
• Perinatal VZV infections are rare and primarily preventable through combined 
active and passive maternal/infant immunization.
• Long-term antiviral treatment of infants with congenital CMV infection and 
associated neurologic sequelae is effective in improving hearing and 
developmental outcome.
• Development of active and passive maternal CMV vaccine strategies is a top 
priority in pediatric health.
Bialas et al. Page 12














What is the current practice?
Congenital CMV infection:
• Screen infants for congenital CMV infection who show signs of congenital 
infection (including microcephaly, petechial rash, hepatosplenomegaly, 
hepatitis, thrombocytopenia, fail the newborn hearing screen).
• Antiviral treatment of CMV-infected infants with neurologic involvement
What changes in current practice are likely to improve outcomes?
• Establishment of the impact of passive CMV hyperimmune globulin on 
congenital CMV transmission
• Implementation of standard congenital CMV screening at birth using infant 
saliva dried blood spots
• Research on the effect of antiviral treatment in congenitally CMV-infected, 
premature and asymptomatic term infants
• Implementation of standard CMV serologic screening and hygiene/behavioral 
CMV avoidance education for all mothers during pregnancy
Is there a Clinical Algorithm?
Major Recommendations:
• Screen infants demonstrating signs consistent with congenital CMV infection 
with urine or saliva HCMV culture or saliva dried blood spot PCR
Bialas et al. Page 13













Figure 1. Clinical manifestations of CMV and VZV infection in neonates
Infants born with congenital CMV or VZV infection can display a wide rane of sequelae, 
many of which can result in permanent developmental and neurological impairment.
Bialas et al. Page 14













Figure 2. Annual number of U.S. children born with long-term pediatric disabilities
Congenital CMV infection in the U.S. causes more long-term pediatric disabilities than 
other common causes of birth defects including FAS, Downs syndrome, spina bifida, HIV, 
Hib, and CRS
Adapted from Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus 
disease epidemic. BMC Public Health 2005;5:70–77; with permission.
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Table 1
Maternal risk factors associated with mother-to-child transmission
CMV VZV
Young age VZV immune status
Non-white race Acute infection at time of delivery
Single marital status
CMV immune status
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